Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 18, 2014 22:05 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Announces Pricing of Its Public Offering of Common Stock

NEWARK, Calif., June 18, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced the pricing of its underwritten public offering of 4,000,000 shares of its common stock at...
June 16, 2014 16:05 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Announces Proposed Public Offering of Common Stock

NEWARK, Calif., June 16, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC) today announced a proposed underwritten public offering of 3,000,000 shares of its common stock pursuant to a...
May 21, 2014 20:50 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Clinical Data to be Presented in "Emerging Technologies" Panel at the International Symposium of Facial Plastic Surgery in New York City

NEWARK, Calif., May 21, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), announced that the company's proprietary, botulinum toxin (BoNTA) investigational products will be the lead...
May 21, 2014 16:20 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics, Inc. Announces Participation in Jefferies 2014 Global Healthcare Conference

NEWARK, Calif., May 21, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced that its management is scheduled to participate in the Jefferies 2014 Global Healthcare...
May 13, 2014 16:01 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Releases First Quarter 2014 Financial Results

NEWARK, Calif., May 13, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today reported financial results for the three months ended March 31, 2014. Revance's operating loss for the...
May 12, 2014 22:25 ET | Source: Revance Therapeutics, Inc

Revance Appoints Mark A. Prygocki to Its Board of Directors

NEWARK, Calif., May 12, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company that develops botulinum toxin products for use in aesthetic and...
April 29, 2014 16:01 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics to Release First Quarter 2014 Financial Results and Host Conference Call on Tuesday, May 13, 2014

NEWARK, Calif., April 29, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), a specialty biopharmaceutical company which develops botulinum toxin products for use in aesthetic and...
April 21, 2014 16:55 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Announces Positive Results From the RT002 Phase 1/2 Study in Glabellar Frown Lines

NEWARK, Calif., April 21, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced positive data from its Phase 1/2 study of RT002 injectable botulinum toxin type A for the...
March 31, 2014 20:00 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Added to Russell 2000(R) and 3000(R) Indexes

NEWARK, Calif., March 31, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today announced the company was added to the Russell 2000® and Russell 3000® Indexes following...
March 26, 2014 16:01 ET | Source: Revance Therapeutics, Inc

Revance Therapeutics Releases Fourth Quarter and Full Year 2013 Financial Results and Provides 2014 Outlook

NEWARK, Calif., March 26, 2014 (GLOBE NEWSWIRE) -- Revance Therapeutics, Inc. (Nasdaq:RVNC), today reported financial results for the three and twelve months ended December 31, 2013. Recent...